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Abstract 
Neuroblastoma is a paediatric cancer with a poor prognosis. This is in part due to the widespread 
metastasis at time of presentation, which is refractory to current treatment modalities. New 
therapeutic agents that can control not only tumour growth but also metastasis are urgently 
needed. 
One current therapeutic option used in the clinic is differentiation therapy with retinoic acid, where 
the terminal differentiation of the neuroblastoma cells reduces tumour growth in the primary 
tumour as well as at metastatic sites. However, retinoic acid only works in a subset of patients.  
We investigated the potential of CDK inhibitors on neuroblastoma cell differentiation, tumour 
progression and metastasis by utilising a 3R compliant cost effective preclinical chick embryo model. 
In both SK-N-AS and BE(2)C cell lines, when engrafted on the chorioallantoic membrane of chick 
embryos, we observed a reduction of tumour cell proliferation as well as a reduction in hypoxia 
preconditioning-driven metastasis by 60%. In addition, the expression of a panel of genes with 
known roles in metastasis, which increased upon hypoxia-preconditioning, was largely reduced by a 
CDK1 inhibitor.  These results provide a promising alternative to currently existing therapies and 
might aid the development of new treatment protocols for retinoic acid-resistant patients. 
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Background 
Neuroblastoma is a paediatric cancer that originates due to delayed development of the neural crest 
cells destined to form the sympathetic nervous system or adrenal glands [1].  Most patients present 
with high risk metastatic disease. However patients presenting before 18 months of age have a 
better prognosis, despite having widespread disease.  This is thought to be due in part to the 
eventual differentiation of tumour cells in younger patients, and has led to the development of 
differentiation therapy, such as retinoic acid, as a strategy for treating neuroblastoma [2, 3]. 
Although the inclusion of retinoic acid in treatment protocols results in enhancement in survival, 
many patients still relapse. In culture, cell lines with amplification of the MYCN gene typically 
respond to retinoic acid whilst cell lines or patients with other genetic modifications such as loss of 
chromosome 11q do not [4], hence the need for additional treatment options for this group. 
Retinoic acid acts by modifying gene expression via complex formation with its receptor RAR and 
downregulation of MYC-N levels. Hence, it is most effective in inducing differentiation in tumours 
with high MYCN expression [5, 6].  Retinoic acid also decreases cell proliferation by increasing levels 
of p27(Kip1), an inhibitor of cyclin D kinase (CDK) 2, 4 and 6 [7]. Decreasing proliferation is thought 
to be intimately associated with the initiation of differentiation during normal development [8] and 
this led us to hypothesise that agents directly inhibiting CDKs may provide an additional or 
alternative approach to promoting differentiation of neuroblastoma cells. CDK inhibitors have 
previously been tested in a range of tumour types including breast cancer where Palbociclib, a CDK 
4/6 inhibitor, has been approved for use in patients [9, 10].  RO-3306, a CDK1 inhibitor, has also 
been successfully tested in preclinical models [11, 12].    
We have previously developed a chick embryo model to enable the investigation of neuroblastoma 
growth and its metastatic process.  We demonstrated that several neuroblastoma cell lines form 
tumours on the chick embryo chorioallantoic membrane (CAM) [13]. We have further shown that 
upon hypoxia preconditioning (1% O2) for three days prior to implantation, cells metastasised into 
the chick embryo from 60% of the tumours observed [13]. This model has further been shown to be 
suitable for therapeutic agents testing [14]. We therefore used it to test whether CDK inhibitors, 
known to slow cell proliferation, may also reduce or prevent metastasis.   
Results 
CDK4/6 inhibitor promotes differentiation of BE(2)C cells while CDK1 inhibitor promotes cell 
death. 
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Previous work has shown that all-trans retinoic acid (ATRA) promotes cell differentiation and 
reduces cell proliferation in some neuroblastoma (NB) cell lines, possibly by increased expression of 
p27Kip1, an inhibitor of CDK2, 4 and 6 [7].  CDK inhibitors, which are known to slow the cell cycle, 
may therefore promote the differentiation of neuroblastoma cells.  To test this hypothesis, BE(2)C 
cells were treated with the CDK4/6 inhibitor Palbociclib (CDK4/6i) for 3 days, alone or in combination 
with ATRA to test whether the CDK4/6i might enhance the ATRA effects on neuroblastoma 
differentiation.  In terms of morphology, while 5 µM of CDK4/6i promoted the growth of cell 
extensions similar to those seen with ATRA, doses of 10 µM and above promoted cell death (Figure 
1A).  Treatment with 5 µM CDK4/6i was enough to reduce the proliferation of BE(2)C cells by 59% 
essentially similar to the ATRA effects (Figure 1B). The combination of the CDK4/6i and ATRA did not 
further decrease cell proliferation (Figure 1C), suggesting that these 2 drugs have similar 
mechanisms of action. To confirm that CDK4/6i was driving BE(2)C cell differentiation, the 
expression of previously characterised markers KLF4, ROBO2 and STMN4, [14] was measured.  In all 
three conditions (drugs alone or in combination), the expression of the stem cell marker KLF4 
decreased whilst the expression of the differentiation markers ROBO2 and STMN4 increased 
compared to untreated cells. Again, CDK4/6i was no more potent than ATRA alone (Figure 1D).  The 
expression of MYCN was not significantly altered in response to the CDK4/6i, whereas a small 
decrease was observed in response to ATRA (Figure 1D). 
CDK4/6 acts at the G1/S boundary, whereas CDK1 acts at both the G1/S and G2/M boundaries. We 
therefore further tested whether a CDK1 inhibitor would have a similar effect to the CDK4/6 
inhibitor.  BE(2)C cells were treated for 3 days with RO-3306, a CDK1 inhibitor. Based on 
morphology, unlike CDK4/6i, RO-3306 promoted cell death in contrast to inhibition of proliferation 
and/or promotion of differentiation even at 5 µM (Figure 2A).  At 1 µM there was no change in 
morphology and no evidence for cell death (data not shown).  Twenty four hour treatment of BE(2)C 
cells with 5 µM RO-3306 followed by two days without drug also resulted in cell death rather than 
any morphological indication of differentiation (data not shown).  To quantify this further, we 
determined cell viability after 3 days and showed that RO-3306 was indeed effective at reducing cell 
viability (Figure 2B).  Three day treatment with 5 µM CDK1i reduced cell viability by 65% and 
increasing the concentration of the inhibitor did not enhance this further.  Using Annexin V labelling, 
we demonstrated that the cell death was apoptotic (Figure 2C). We also noticed that 5 µM CDK4/6i, 
shown above to promote differentiation, also prompted cell death by apoptosis of some cells (Figure 
2C).    
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CDK4/6 and CDK1 inhibitors promote cell death of SK-N-AS cells 
SK-N-AS cells express MYCN but do not have amplification of the MYCN gene.  Instead they have an 
11q deletion and thus represent the genetic signature of another group of patients with poor 
prognosis [4].   SK-N-AS cells do not differentiate or indeed respond to ATRA alone [15] so being able 
to target 11q- cells with an alternative approach would be very beneficial. As shown in Figure 3A the 
response of the SK-N-AS to both CDK4/6i and CDK1i was cell death at 5 µm, with no evidence of a 
change in morphology towards a differentiation phenotype at lower doses (1 µm).  Cell viability was 
assessed after three days and again CDK1i prompted extensive cell death (58%) at 5 µM with no 
significant increase at higher concentrations (Figure 3B).  CDK4/6i was less efficient in inducing cell 
death at 5 or 10 µM (Figure 3B), but there was still evidence of increased apoptosis at 5 µM (Figure 
3C).     
 
CDK4/6 and CDK1 inhibitors reduce cell proliferation in both BE(2)C and SK-N-AS tumours  
Cells can respond differently to drugs in a 3D in vivo environment compared to a 2D culture, so it 
was essential to test the efficacy of these drugs on tumours formed in vivo. We have used the chick 
CAM model, which not only allows robust neuroblastoma tumour formation, but also the control of 
their metastatic phenotype through hypoxic preconditioning [13].  We have previously shown that 
using four times the in vitro concentration of ATRA in the chick, tumours had significantly reduced 
number of proliferating cells, with cells also expressing differentiation markers [14].  We injected 
CDK inhibitors to give a concentration of 20 µM (in the egg), after tumour formation at embryonic 
day 11 (E11) and E13 and the treated tumours were harvested at E14.  The chick embryos tolerated 
the doses well with no significant change in embryo survival (data not shown).  Ki67-staining of 
BE(2)C tumour sections revealed a reduction in cell proliferation in response to both CDK4/6i and 
CDK1i (Figure 4A and C).  CDK4/6i reduced cell proliferation of BE(2)C cells by 35%, similar to ATRA 
(39%) (Figure 4B).  Contrary to in vitro data, CDK1i proved more efficient than CDK4/6i, reducing cell 
proliferation by almost 50%.  Similar experiments were carried out with SK-N-AS cells.  Since ATRA 
has no effect on SK-N-AS [15], only the two CDK inhibitors were tested.  The reduction in 
proliferation was similar to that seen with BE(2)C cells (40% and 50% for CDK1i and CDK4/6i 
respectively; Figure 4D).  
Since, both inhibitors had a marked effect on cell survival and triggered apoptosis in cultured cells, 
we used TUNEL staining to evaluate the amount of apoptosis in the tumours.  The number of cells 
dying by apoptosis was very small in control tumours (<2%).  This result was consistent with the 
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number of apoptoticcells observed by histology (Supplementary figure).   None of the inhibitors 
triggered a significant increase in either BE(2)C or SK-N-AS tumours (Figure 4 E,F). Thus, unlike in in 
vitro cell culture, the main effect of the CDK inhibitors was a reduction in cell proliferation, rather 
than an increase in apoptosis  
CDK inhibitors reduce hypoxia/DMOG-induced metastasis 
We next investigated the effects of the CDK inhibitors on neuroblastoma metastasis. We have 
previously shown that preconditioning neuroblastoma cell lines for three days in 1% O2 or 
pretreatment for 24 h with the hypoxia mimetic drug DMOG promotes metastasis of cells from the 
tumour formed on the CAM into the embryo [13]. Prior to the in vivo investigation, we initially 
tested whether ATRA could reverse the effect of DMOG on the BE(2)C cells proliferation in vitro.  As 
shown in Figure 5A and B, DMOG increased cell proliferation by 45% in vitro and ATRA reversed this 
increase, by reducing proliferation to control levels, although not to the level of ATRA treatment on 
non-DMOG treated cells.  The effect of the CDK inhibitors on the viability of control and DMOG pre-
treated cells was also tested.  Both inhibitors reduced the viability of cells (BE(2)C and SK-N-AS) 
irrespective of the DMOG treatment (Figure 5C & D). 
We further tested the CDK inhibitors and ATRA, for their ability to block the metastatic process in 
vivo.  We have previously shown that by pre-treating cells with DMOG for 24 h or growing cells in 1% 
O2 for 3 days prior to implanting the cells on the CAM, triggered metastasis in 60% of the cases, 
often in the liver and gut [13].  Such a metastatic phenotype was never observed with tumours 
formed from cells grown in normoxia.  Before testing the effect of the drugs we first needed to 
determine the onset time of metastatic dissemination by dissecting the embryos at E9 – E13.  
Tumour formation could first be detected at E11 for BE(2)C cells and E10 for SK-N-AS cells, yet in 
most cases metastatic cells were only observed after E12.  We therefore changed the treatment 
regime from injections at E11 and E13 to E10 and E12 to ensure that the inhibitors were introduced 
before to the onset of metastasis.   
Tumours were formed from SK-N-AS cells that had been pre-treated with DMOG for 24 h. 
Approximately 80% of tumour cells were Ki67 positive in the DMOG tumours, a proportion similar in 
tumours formed by cells that had not been exposed to DMOG (Figure 4D and & 6A).  Both CDK 
inhibitors reduced cell proliferation in the DMOG tumours by 24-39% for cdk4/6i and cdk1 I 
respectively (Figure 6A).   
BE(2)C cells were overall less efficient at forming tumours on the CAM than SK-N-AS cells (70% vs 
90% for SK-N-AS) and DMOG pre-treatment affected the efficiency of tumour formation for these 
(which was not peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint. http://dx.doi.org/10.1101/405639doi: bioRxiv preprint first posted online Aug. 31, 2018; 
cells.  We therefore replaced the DMOG pre-treatment by hypoxia preconditioning (1% O2 for 3 
days).  Approximately 65% of tumour formed by cells subjected to hypoxia were Ki67 positive 
compared to 70% for tumours formed by cells grown in normoxia (Figure 4B and 6B).  Upon 
treatment with the cdk inhibitors, a small decrease in proliferation was observed although none was 
significant (Figure 6B).  Thus a similar but smaller effect was observed with these agents compared 
to tumours formed from cells grown in normoxia (Figure 4C).   
DMOG-pretreated SK-N-AS cells efficiently formed tumours and more than 95% of embryos with 
tumours on the CAM, also had cells or small clumps of cells disseminated in the chick organs at E14 
(detected by fluorescence upon dissection).  The liver and gut were typical locations for metastatic 
cells, with occasional occurrence in the meninges (Figure 7A).  We initially observed that DMSO 
alone had an impact on metastasis occurrence. DMSO above 100 µl in total is reported to 
compromise chick survival [16] and although chick survival was not affected in our hands with a final 
volume of 130 µl, it did reduce the ability of tumour cells to metastasise.  We reduced the number of 
injections from two to one and with a single injection of CDK1i or DMSO at E10, the effects of DMSO 
were comparable to PBS controls and significantly different to the CDK1i (Figure 7C; 80% metastasis 
with DMSO alone versus 33% with CDK1i).  CDK4/6i was dissolved in PBS, but for comparison, we 
also gave only one injection at E10.  In this case the metastasis frequency was reduced from 92% to 
44% (Figure 7C).   
Similar experiments were conducted with BE(2)C cells.  The distribution of metastatic cells was 
similar to that observed for SK-N-AS (Figure 7B) and CDK1i reduced metastasis by almost 60% (from 
76% to 31%) while CDK4/6i reduced metastasis by 56% (from 83% to 36%) (Figure 7D).  ATRA was 
introduced into the allantoic sac in 11.5 µl of DMSO (due to the greater solubility of ATRA in DMSO). 
Its effect with one and two injections was measured as comparison.  One injection reduced 
metastasis from 80% to 60% while two injections reduced it from 64% (two injections of DMSO) to 
27%.  Thus ATRA was less efficient at reducing metastasis than either of the CDK inhibitors but it was 
interesting that the second injection was able to significantly reduce metastasis supporting the 
notion that metastasis was mainly occurring between E12 and E14 in this model (Figure 7D).   
CDK1i partially reverses hypoxia driven changes in gene expression 
We have previously observed significant changes in the expression of more than 20 genes thought to 
be important in the metastatic process in response to both hypoxia and DMOG pre-conditioning 
[13].  In order to provide some insight into the mechanism by which the CDK inhibitors might be 
acting on the metastatic process, we selected eight of these genes to test for their response to CDK1i 
(Figure 8).  Tumours were formed from normoxic cells or from cells treated with DMOG (SK-N-AS) or 
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hypoxia (BE(2)C).  The tumours formed by hypoxic preconditioned cells were then treated with 
either CDK1i or an equivalent volume of DMSO at E10.  The mRNA levels in the hypoxia-
preconditioned tumours were compared with those in the normoxic tumours.  For both BE(2)C and 
SK-N-AS tumours, the eight genes responded as reported previously [13] with almost all changes 
reaching significance (Figure 8A&B).   
A comparison of hypoxia-treated tumours with and without CDK1i revealed that CDK1i reversed the 
observed upregulation of expression in the seven up-regulated genes whilst VCAN, whose 
expression was down-regulated showed a small increase in expression (Figure 8C&D).  In some cases 
expression levels returned to those seen in the normoxic tumours.  Taken together these result 
strongly suggest that a single dose of CDK1i reduces the metastatic phenotype and activity of cells 
pre-conditioned in hypoxia/treated by DMOG by reversing the increase in expression of genes that 
are implicated in hypoxia-driven metastasis. In conclusion, we have demonstrated the efficacy of 
CDK inhibitors in inhibiting neuroblastoma growth and metastasis in vivo, regardless of the MYC-N 
amplification status of the cells, thereby offering potential alternative therapeutic avenue compared 
to the commonly used ATRA. 
 
Discussion 
The chick embryo is an increasingly valuable model for analysing tumour formation, angiogenesis 
and most recently the metastatic behaviour of tumour cells.  Development of new and effective 
therapies require a suitable and efficient preclinical model.  Here we have demonstrated the value of 
the chick embryo model for screening potential therapeutic agents for their ability to reduce tumour 
growth and limit metastasis of neuroblastoma cell lines.  CDK inhibitors reduced cell proliferation in 
tumours in contrast to their in vitro activity of driving high levels of cell death.  The conspicuous 
difference between in vitro and in vivo activity may be due to differing concentration of inhibitor 
experienced by the cells however lower concentrations in culture did not show any change in cell 
proliferation.  The cellular response to agents in the complex 3D environment of a tumour can be 
different to that seen in 2D cultures as has been observed by others [17, 18] and this may be the 
more likely explanation for the differences observed demonstrating yet again the value of the in vivo 
model.  Metastasis was judged to have occurred if fluorescent cells were found in the embryo by 
dissection under a fluorescent stereomicroscope.  Single cells within in the embryo could be 
identified making this more efficient than previous methods of detecting metastatic cells [19].  
Careful dissection of many embryos here and previously [13, 14] revealed the typical locations for 
the metastatic cells.  The most common locations were associated with the intestines in the 
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peritoneal cavity or the liver.  No metastatic cells were seen prior to the formation of a primary 
tumour on the CAM and they were only seen in embryos that formed a primary tumour.  This 
confirms that the cells within the embryo were derived from the primary tumour rather than from 
the initial implantation of cells on the CAM at E7 [13, 14, 20-23].  Thus the CAM tumour model is 
excellent for investigating response mechanisms to new therapeutic agents in a cost-effective and 
timely manner.   
CDK1:cyclin B complex is sufficient to drive mammalian cells through the cell cycle via 
phosphorylation of Rb and the consequent activation of the E2F expression program [24].  Inhibiting 
CDK1 generally arrests the cell cycle at the G2/M boundary and can result in cells undergoing 
apoptosis [25].Thus CDK1 makes an attractive target although it should be noted that CDK1 is also 
responsible for a key phosphorylation step that primes MYCN for degradation [26].  CDK4/6 
promotes progression through the G1/S boundary also by phosphorylation of Rb.  Components of 
the CDK4/6 pathway are often dysregulated in cancer making this complex a promising target for 
treatment [27].  Like CDK1, CDK4 and 6 activate a number of additional pathways and the 
consequence of inhibiting these kinase may be variable in different tumours [27].  The Inhibitor 
palbociclib has variable sensitivity across a number of neuroblastoma cell lines [28], furthermore, 
LEE011, an alternative CDK4/6 inhibitor prompted apoptosis in the majority of neuroblastoma cell 
lines tested and a reduction in proliferation in BE(2)C xenograft tumours in mice [29] consistent with 
our results.   
Hypoxia drives an aggressive, invasive phenotype and many effects are mediated by HIF1-α.  Targets 
of HIF1-α include proteins involved in invasion, intravasation, adhesion and extravasation and these 
are likely to be responsible for the change in the neuroblastoma cells to a metastatic phenotype.  
CDK1, 4 and 6 have been shown to directly increase the stability of HIF1-α by two different 
mechanisms.  CDK1 phosphorylates HIF1-α on Ser688, a modification that reduces the degradation 
of HIF1-α [30].  CDK4/6 phosphorylates prolyl hydroxylase 1 (PHD1), one of the enzymes responsible 
for degrading HIF1-α in the presence of O2 [31].  Phosphorylation alters the interaction between PHD 
and HIF1-α potentially stabilising HIF1-α.  Both these CDK activities occur independently of O2 levels.  
Inhibiting these CDKs is expected to reduce the abundance of HIF1-α, an effect that should be most 
obvious under hypoxic conditions when HIF1- α is normally stabilised.  Here we find that treatment 
with the CDK1i, RO-3306, can partially reverse the hypoxia-induced expression pattern in the tumour 
several days after this pattern has been established in culture.   
Blocking the cell cycle via CDK inhibitors is an attractive approach to treating many cancers and had 
the added value here of potentially prompting differentiation.  Some neuroblastoma cell lines and 
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some tumours respond well to retinoic acid by adopting a less aggressive more differentiated 
phenotype and it is well established that tumours with differentiation markers such as TrkA have a 
better prognosis.  SK-N-AS, along with a number of other cell lines, has not been shown to 
differentiate so far.  However, since both CDK inhibitors reduced cell proliferation in the SK-N-AS 
CAM tumours, a prerequisite to initiating differentiation, it would be interesting to investigate 
whether the cells did begin to move down the differentiation pathway in vivo. 
In conclusion, CDKi provide promising alternatives to ATRA for both reduction of tumour 
development but also of its dissemination. In addition, they have the potential to be effective in a 
range of neuroblastoma genetic background, and unlike ATRA, are not restricted to MYCN amplified 
tumours. The fact that they have been trialled in clinic for other tumour types should facilitate their 
deployment for neuroblastoma in a near future. 
 
Methods and Materials: 
Cell culture 
BE(2)C (human NB, ECACC No. 95011817) and SK-N-AS (human NB, ECACC 94092302) were grown in 
minimal essential medium DMEM (Life Technologies), 10% Foetal Bovine Serum FBS (Biosera, East 
Sussex, UK ), 100 U/ml penicillin,100 μg/ml streptomycin ( Sigma, P0781) and 1% Non-Essential 
Amino Acids (Sigma, M7145).  They were maintained at 37°C with 5% CO2 were passaged using 
0.05% Trypsin/EDTA (Sigma Aldrich). Cell lines were transduced with green fluorescent protein (GFP) 
lentivirus as described previously [13, 22].  For hypoxic studies, cells were maintained at 37 °C with 
5% CO2 and 1% O2 (Don Whitley Scientific, Shipley, UK; Hypoxystation-H35) for 72 h. For 
dimethyloxallylglycine (DMOG) treatment, cells were cultured in media supplemented with 0.5 mM 
DMOG (Enzo Laboratories, Farmingdale, NY, USA) for 24 h.  Treatments were performed with all 
trans retinoic acid (ATRA, Sigma), the CDK4/6 inhibitor Palbociclib (Selleckchem) or CDK1 inhibitor 
RO-3306 (Sigma) at indicated concentrations and timings.    
Cell Proliferation Assays and Morphology Analysis  
25x103 cells/ml of BE(2)C cells were plated onto coverslips in a 24 well plate, and incubated for 18-
24 h to adhere.  Cells were treated with DMOG for 24 h then the media was replaced by media 
containing all trans retinoic acid (ATRA) (10 µM) or Palbociclib (5 µM) or both for a further 72 h.  
Controls were DMSO (0.06% v/v) or PBS respectively. To assess the morphology of cells, images of 
cells were obtained using an inverted microscope (Leica DMIRB) prior to fixation.  For 
immunocytochemistry, cells were fixed with 4% paraformaldehyde for 10 min, blocked with 1% BSA, 
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0.1% Triton X100 in 0.12 M phosphate pH7.4 for 30 minutes and stained overnight at 4°C with 1:50 
dilution of Ki67 (Abcam ab16667) diluted in blocking buffer.  Coverslips were incubated in goat anti 
rabbit Alexa 594 (Life Technologies) 1:500 for 1 h at room temperature in blocking buffer.  Cell nuclei 
were stained with DAPI (Sigma).  Proliferating cells were quantified by Ki67 staining and normalised 
to the total number of nuclei stained by DAPI.  At least three fields per coverslip and 3 coverslips per 
experiment were counted and a minimum of 300 cells per condition.  
MTT assay 
The MTT assay was used to measure cell viability after Palbociclib and CDK1i treatment. BE(2)C cells 
and SK-N-AS cells were seeded at 5x104 cells/ml into 96 well plates (Costar, Cat no. 3596) with 100 μl 
of medium and left to adhere for 18-24 h at 37°C 5% CO2. Cells were cultured in media 
supplemented with or without 0.5 mM DMOG for 24 h.  Cells were then treated for a further 72 h 
with medium containing Palbociclib or CDK1i. To analyse cell viability, 5 μl of (5 mg/ml) MTT (Sigma) 
was then added to each well (100 μl), for 4 h at 37 °C.  100 μl of stop solution (10% SDS in 0.01 M 
HCl) was added for 1 min. The plate was incubated at 37°C and 5% CO2 overnight and absorption at 
570 nm was read.  All MTT assays were repeated three times. 
Apoptosis determination in unfixed cells 
25x103 cells/ml of BE(2)C and SK-N-AS cells were plated onto coverslips in a 24 well plate, incubated 
for 18-24 h, treated for 72 h with medium containing Palbociclib (5 µM) or CDK1i (5 µM); or 
PBS/DMSO as control. Apoptotic cells were identified using Apoptotic/Necrotic/Healthy Cells 
Detection Kit from Promokine (PK-CA707-30018) according to the manufacturer’s instructions. Cells 
were washed twice with 1X Binding Buffer and then incubated with a staining solution  (5 μl of FITC-
Annexin V, 5 μl of Ethidium Homodimer III and 5 μl of Hoechst 33342 in 100 μl 1X Binding Buffer, 
1:20 dilution) for 15 minutes at RT, protected from light. Apoptotic cells were quantified by FITC-
Annexin V staining and normalised to the total number of nuclei stained by Hoechst 33342.   
Chick embryo CAM Assays 
Fertilised white leghorn chicken eggs were obtained from Tom Barron, Preston, UK. Eggs were 
incubated at 38°C and 35-40% humidity and windowed at E3 as described previously [22].  For 
tumour formation 2x106 GFP-labelled cells were applied to the CAM of each embryo [13]. To 
increase the tumour yield, the CAM was traumatised using a strip of sterile lens tissue causing a 
small bleed [32] followed by the addition of 5 µl of 0.05% trypsin 0.5mM EDTA.  Eggs were resealed 
and incubated until E14 [23].  Ethical approval for all experiments involving chick embryos was 
obtained from the Liverpool Animal Welfare and Ethical Review Body.   
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Drug delivery 
11.3 µl of 0.16 M ATRA in DMSO was diluted to 200 µl with PBS and the colloidal solution was 
injected into the allantoic sac where the ATRA re-dissolved.  ATRA was injected at E11 and E13 for 
normoxic tumours or E10 followed, in some experiments, by a second injection at E12 for hypoxic 
tumours.  90 µl of 10 mM Palbociclib in PBS was diluted to 200 µl in PBS and the solution was 
injected as for ATRA.  65 µl of 14 mM CDK1i in DMSO was diluted to 200 µl with PBS and the solution 
was injected.  Final concentration of the drugs in the egg, assuming 45 ml per egg was 40 µM for RA 
and 20 µM for the CDK inhibitors per injection.  200 µl of PBS was injected as a control for 
Palbociclib, 200 µl of 6.6% DMSO as control for ATRA and 200 µl of 32.5% DMSO as control for 
CDK1i.  Embryos were dissected on E14 and tumours analysed. 
 
Quantitative PCR 
In vitro samples: cells were seeded at a density of 2x106 per 75 cm2 flask and after 24 h, treated with 
either ATRA (10 µM), Palbociclib (5 µM) combination of both or DMSO alone as control. Every 48 h 
the medium was replaced with fresh medium as appropriate. After 3 d, RNA was extracted using 
RNA mini Kit (QIAGEN) according to manufacturer’s instructions. qPCR was carried out on CFX 
Connect (Biorad) thermocycler using iTaq Universal SYBR green mix (Biorad) with 0.5 µM primers 
and up to 2 µl cDNA for 35 cycles.  An annealing temperature of 60°C was used for all primer pairs 
and three technical replicates and at least three biological replicates were carried out for each 
sample.  qPCR data analysis was carried out using Bio-Rad CFX Manager 3.0 software. Normalised 
relative expression of target genes compared to housekeeping genes (GAPDH, HPRT1 and UBC) was 
calculated using the ΔΔCq analysis mode [33].  
In vivo: tumours formed from normoxic cells, hypoxic cells and hypoxic cells after CDK1i application 
at E10 (20 µM) were harvested from the CAM, rinsed in phosphate-buffered saline (PBS), then 
transferred into RNAlater solution (QIAGEN), and stored at initially at 4°C or -20°C for longer term 
storage prior to RNA extraction. Tissue was first removed from the RNAlater and transferred to a 
clean RNase free falcon tube. Liquid nitrogen was used to freeze the tissue before a pestle and 
mortar was used to disrupt it. RNA was then extracted using RNA mini Kit (QIAGEN).  qPCR was 
performed as described above.  A list of the primers used is provided in Table 1.  
One tumour for each condition (normoxia, hypoxia, hypoxia followed by injection of 200 µl of 
4.5 mM CDK1i at E10 or hypoxia followed by 200 µl of 32.5% DMSO at E10) was obtained from a 
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single experiment and fold change was analysed.  The experiment was repeated three times and 
statistical analysis performed on the fold change derived from each experiment.   
Immunohistochemistry  
Tumours harvested for paraffin embedding were fixed for 2 h in 4% paraformaldehyde (PFA) or 10% 
formalin and then embedded in paraffin using standard protocols.  4 µm sections underwent antigen 
retrieval and were stained using the DAKO Autostainer (K8012) as described previously [14].   
Sections were incubated for 30 min with Ki67 antibody (1:200) (DAKO M7240) in 5% BSA in Tris 
Buffered Saline followed by goat anti-mouse HRP (Abcam)(1:250) and staining with 3,3’-
diaminobenzidine DAB (1 drop per ml). Haematoxylin staining was performed on all the slides to 
assist in distinguishing between tumour and chick nuclei. A total of 9 fields from 3 slides were 
counted per tumour and at least three tumours per condition were analysed.   
TUNEL Assays 
TUNEL assay was performed on tumour sections prepared as above using the DeadEnd™ 
Colorimetric TUNEL System (G7130) kit according manufacturer’s instructions (Promega, Madison, 
WI, USA). TUNEL-positive nucleus was identified as apoptotic cells. Cell counting was performed on 
at least three tumours per condition, 9 fields from 3 slides per tumour were counted and analysed.  
Statistical analysis 
Statistical significance was computed using Student’s t-test or one-way ANOVA followed by a post-
hoc tukey test using SPSS. All data are presented as mean ±SEM. (standard error of the mean). 
Data Availability 
The datasets generated during and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
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Figure 1. The CDK4/6i and ATRA promote differentiation of BE(2)C cells and CDK4/6i induces death 
at 10 and 20 µM. A BE(2)C cells were treated for 3 days with DMSO, 5 µm, 10 µm, 20 µm CDK4/6i, 
10 µm ATRA and 5 µm CDK4/6i and 10 µm ATRA combined.  5 µm CDK4/6i, 10 µm ATRA and the 
combination all showed a change in morphology including cellular extensions of variable length. 10 
µm and 20 µm CDK4/6i showed increasing numbers of floating cells indicative of cell death.  B  GFP-
expressing BE(2)C cells were grown for 3 days in 5 µm CDK4/6i, 10 µm ATRA and both combined and 
then stained for Ki67 (red) and DAPI (blue).  C Quantification of Ki67-positive cells as a percentage of 
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the total cell number.  All three treatments showed a 59% reduction in cell proliferation.  Each bar 
represents the mean ±SEM of three independent experiments (n = 3) and at least 9 fields per 
experiment. *** P⩽0.001 compared with the control. Scale bar =100 µM.  D Relative mRNA levels 
for the target genes were determined by qPCR.  Cells were cultured with either 5 µM of CDK4/6i, 
10 µM of ATRA or in combination for 3 days.  At least three independent experiments (n = 3) were 
analysed for each condition and mRNA levels are displayed relative to GAPDH, UBC and HPRT1 and 
normalised to cells cultured for 3 days with DMSO (ATRA) or PBS (CDK4/6i). Each bar in the graph 
represents the normalised mean± SEM of three independent experiments. *P⩽0.05, **P⩽0.01 and 
***P⩽0.001 compared with control. 
Figure 2. CDK1i reduces cell viability and induces apoptosis in BE(2)C cells. A  BE(2)C cells were 
treated for 3 days with DMSO, 5 µm, 10 µm, 20 µm CDK1i.   Increasing CDK1i concentration resulted 
in increasing numbers of floating cells indicative of cell death.  B Cells were cultured for 72 h with 1, 
5, 10, and 20 µM of CDK4/6i, CDK1i, or PBS (CDK4/6i) or DMSO (CDK1i) as control.  MTT assay was 
carried out and the OD was measured at 570 nm.  Data are the mean ±SEM of five independent 
experiments (n = 5), with 3 technical replicates for each treatment. *P⩽0.05 and **P⩽0.01. C Cells 
were treated for 72 h with media containing either CDK4/6i (5 µM) or CDK1i (5 µM) or DMSO as 
control. Cells undergoing apoptosis were visualised with Annexin V-FITC (green) and cells were 
identified with Hoechst 33342 (blue). Scale bar =100 µM.  
Figure 3. Both CDK4/6i and CDK1i induce apoptosis in SK-N-AS cells. A Cells were cultured for 3 
days with 5 µM, 10 µM, and 20 µM CDK4/6i, CDK1i, or PBS/DMSO control.  Increasing inhibitor 
concentration resulted in increasing numbers of floating cells indicative of cell death.   B  Cells were 
cultured for 72 h with 1 µM, 5 µM, 10 µM, and 20 µM of CDK4/6i, CDK1i, or PBS/DMSO control and 
measured at 570 nm.  MTT assay was carried out and the OD was measured at 570 nm.  Data are the 
mean ±SEM of five independent experiments (n = 5), with 3 technical replicates for each treatment. 
**P⩽0.01 and ***P⩽0.001 compared with control. Cells were treated for 72 h with media 
containing either CDK4/6i (5 µM) or CDK1i (5 µM) and or DMSO as control. Cells undergoing 
apoptosis were visualised with Annexin V-FITC (green) and cells were identified with Hoechst 33342 
(blue).  Scale bar =100 µM.  
Figure 4. CDK4/6i and CDK1i reduce cell proliferation of BE(2)C and SK-N-AS cells within tumours. 
A  GFP-labelled BE(2)C cells were implanted on the CAM of E7 chick embryos. Two injections of 
0.2 ml of 9 mM ATRA, 4.5 mM CDK4/6i, 4.5 mM CDK1i, 14% DMSO, PBS, 32.5% DMSO as control 
respectively were made into the allantoic sac of embryos at E11 and E13. Dissected tumours were 
formalin-fixed and paraffin embedded and 4µm sections were stained with Ki67 (brown). ATRA, and 
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both CDK1i and CDK4/6i reduced the number of Ki67 positive tumour cells  B Quantification of Ki67-
positive cells as a percentage of the total cell number indicates a reduction in cell proliferation for 
each of the three treatments.  Each bar represents the mean ±SEM of three independent 
experiments and at least 9 fields counted per experiment, *P⩽0.05 and ***P⩽0.001 Scale bar is 
100 µM. C formalin-fixed and paraffin embedded (FFPE) SKNAS sections stained with Ki67. GFP-
labelled SKNAS cells were implanted on the CAM of E7 chick embryos. Two injections of 0.2 ml of 4.5 
mM CDK4/6i, 4.5 mM CDK1i, or PBS, 32.5% DMSO as control were into the allantoic sac of embryos 
at E11 and E13. 4 µm  FFPE sections were stained with Ki67 (brown).  Both CDK1i and CDK4/6i 
reduced the number of Ki67 positive tumour cells.  D Quantification of Ki67-positive cells as a 
percentage of the total cell number indicates a reduction in cell proliferation for both treatments.   
Each bar represents the mean ±SEM of three independent experiments (n = 3) and at least 9 fields 
counted per experiment, *P⩽0.05 and **P⩽0.01. Scale bar =100 µM. E Quantification of TUNEL-
positive cells as a percentage of the total cell number of BE(2)C cells within the section, the data is 
from three tumours and 9 fields per tumour and is shown here as mean ± SEM (n = 3).  F 
Quantification of TUNEL-positive cells as a percentage of the total cell number SK-N-AS cells within 
the section, the data is from three tumours and 9 fields per tumour and is shown here as mean ± 
SEM (n = 3). ).*P ⩽0.05 compared with control. 
 
Figure 5. The effect of ATRA, CDK4/6 and CDK1 inhibitors on DMOG-treated BE(2)C and SK-N-AS 
cells. A  BE(2)C cells were pretreated with DMOG for 24hr followed by 3 days with or without 10 µM 
ATRA.  For comparison cells without DMOG were also treated with ATRA.  Cells were then stained 
with Ki67 (red) and DAPI stained (blue)  Scale bar =100 µM. B Quantification of percentage of Ki67-
positive cells indicates a reduction in cell proliferation following treatment with 10 µM of ATRA in 
both DMOG- treated and control BE(2)C cells. Each bar represents the mean ±SEM of three 
independent experiments (n = 3) and at least 9 fields per experiment. ***p⩽0.001 compared with 
the control. C BE(2)C cells were grown +/- DMOG for 24 h and then treated with CDK4/6i, CDK1i or 
medium with now drug for 3 days.  The number of viable cells was assessed using the MTT assay.  
CDK4/6i and CDK1i both reduced the cell number irrespective of whether the cells were 
precondition in DMOG. Displayed is the mean ±SEM of at least three independent experiments (n = 
3), with 3 technical replicates in each treatment.*P⩽0.05 and **P⩽0.01 compared with the control. 
D Same as for C but with SK-N-AS cells. 
 
Figure 6. The effect of CDK4/6i and CDK1i on cell proliferation of hypoxia-preconditioned SK-N-AS 
and BE(2)C cells in tumours. A  SK-N-AS were pre-treated with DMOG for 24 hr prior to implantation 
at E7 on the CAM of chick embryos. Two injections of 200 µl of 4.5 mM CDK4/6i or 4.5mM CDK1i, or 
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PBS, 32.5% DMSO as control respectively were made into the allantoic sac of embryos at E10 and 
E12.  Tumours were sectioned and stained for Ki67.  The percentage of Ki67 positive cells is shown 
and each bar represents the mean ±SEM of three independent experiments (n = 3) and at least 9 
fields per experiment.*P⩽0.05 and **P⩽0.01 compared with the control. B Quantification of Ki67-
positive cells out of the total cell number BE(2)C forming- tumours. BE(2)C cells were cultured in 1% 
O2 for 3 days prior to implantation at E7 on the CAM of chick embryos. Two injections of 9 mM RA, 
4.5 mM CDK4/6i, 4.5 mM CDK1i, or 6.6% DMSO, PBS, 32.5% DMSO as controls respectively were 
made into the allantoic sac of embryos at E10 and E12. Tumours were sectioned and stained for 
Ki67.  The percentage of Ki67 positive cells is shown and each bar represents the mean ±SEM of 
three independent experiments (n = 3) and at least 9 fields per experiment. 
Figure 7. Hypoxic pre-conditioning of cells triggers metastasis in vivo and CDK inhibitors reduce 
this. A Representative images of metastatic SKNAS cells in embryonic organs. Hypoxic GFP-labelled 
SKNAS cells were implanted on the CAM of E7 chick embryos. At E14 embryos were dissected using 
fluorescence and organs containing metastatic cells were imaged. Scale bar is 500 μm. B 
Representative images of metastatic BE(2)C cells as for A. C Embryos with SK-N-AS cells implanted on 
the CAM at E7 were treated with a single injection of 200 µl of either 4.5 mM CDK1i or 32.5 DMSO at 
E10.  All embryos with CAM tumours formed from SK-N-AS cells were dissected at E14 and the 
percentage of embryos with metastatic cells for each treatment was calculated.  A minimum of 15 
embryos per condition was analysed (n=15-18).  D Embryos with BE(2)C cells implanted on the CAM 
at E7 were treated with a single injection of 200 µl of 9 mM ATRA, 4.5 mM CDK4/6i, 4.5 mM CDK1i, 
14% DMSO, PBS, 32.5% DMSO as control at E10.  All embryos with CAM tumours formed from 
BE(2)C cells were dissected at E14 and the percentage of embryos with metastatic cells for each 
treatment was calculated.  A minimum of 12 embryos per condition was analysed (n=12-19).  
Figure 8. Hypoxia-triggered changes in gene expression is reversed by CDK1i in both BE(2)C and 
SKNAS tumours. A Comparison of gene expression between BE(2)C tumours formed from cells 
grown in 21% O2 and cells pre-cultured in 1% O2 for 3 days prior to implantation on the chick CAM at 
E7.  B Comparison of gene expression between normoxia and hypoxic SKNAS tumours prepared as 
for BE(2)C tumours above.  C Comparison between BE(2)C tumours formed from cells pre-cultured in 
1% O2 for 3 days prior to implantation on the chick CAM at E7 treated at E10 with either CDK1i or 
DMSO.  D  Comparison between SK-N-AS tumours formed from cells pre-cultured in 1% O2 for 3 days 
prior to implantation on the chick CAM at E7 treated at E10 with either CDK1i or DMSO.    
At least one tumour for each condition was obtained from a single experiment and used for 
comparison.  mRNA levels were normalised to GAPDH, UBC and HPRT1 in each case and each bar in 
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the graph represents the normalised mean ±SEM of at least three independent experiments. 
*P⩽0.05, **P⩽0.01 and ***P⩽0.001 compared with normoxia (A and B) or hypoxia (C and D).  
 
Table 1: List of primer names and sequences for qPCR 
Gene  Gene name Forward 5’-3’ Reverse 5’-3’ 
GAPDH glyceraldehyde-3-
phosphate 
dehydrogenase 
AATCCCATCACCATCTTCCA 
 
TGGACTCCACGACGTACTCA 
HPRT1 hypoxanthine 
phosphoribosyltransfe
rase 1 
TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
UBC ubiquitin C ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 
KLF4 Kruppel-like factor 4 CGCCGCTCCATTACCAAGAGC CGGTCGCATTTTTGGCACTG 
MYCN Neuroblastoma-
derived v-myc avian 
myelocytomatosis 
viral related oncogene 
CACAAGGCCCTCAGTACCT ACCACGTCGATTTCTTCCTCT 
ROBO2 roundabout, axon 
guidance receptor, 
homolog 2 
GATGTGGTGAAGCAACCAGC 
 
TGGCAGCACATCTCCACG 
ADAMT
S1 
ADAM 
metallopeptidase with 
thrombospondin type 
1 motif,1 
CCCTCACTCTGCGGAACTTT GGACCCACACAAGTCCTGTC 
GLUT1 Glucose transporter 1, 
also SLC2A1 
GAACTCTTCAGCCAGGGTCC 
 
ACCACACAGTTGCTCCACAT
ITGαV Integrin, alpha V CGCTTCTTCTCTCGGGACTC AGAAACATCCGGGAAGACGC 
ITGβ5 Integrin, beta 5 GGGAGCCAGAGTGTGGAAAC GGATCGCTCGCTCTGAAACT 
MMP9 Matrix 
metallopeptidase 9 
TTCTGCCCGGACCAAGGATA ATGCCATTCACGTCGTCCTT
VCAM Vascular cell adhesion 
molecule 1 
TGTTTGCAGCTTCTCAAGCTTTTA GTCACCTTCCCATTCAGTGGA 
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VCAN Versican ACCAGACAGGCTTCCCTCCCC GGGTGATGCAGTTTCTGCGAGGA
VEGF Vascular endothelial 
growth factor 
CTCCACCATGCCAAGTGGTC GCAGTAGCTGCGCTGATAGA 
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Figure 2 
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Figure 3 
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